The DOI matches its Crossref record.
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment
Open accessAbstract
Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 months of starting imatinib; however, some patients achieved initial MCyR and CCyR more than 5 years after imatinib initiation. Estimated rates of freedom from progression to accelerated phase (AP) and blastic phase (BP) and overall survival at 6 years were 61% and 76%, respectively. Both freedom from progression to AP/BP and overall survival (OS) were associated with cytogenetic response level at 12 months. No increase in rates of serious adverse events was observed with continuous use of imatinib for up to 6.5 years, compared with earlier time points. Imatinib continues to be an effective and safe therapy for patients with CP CML after failure of IFN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Translation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
Self-citationSoverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 589
Self-citationKantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L., Goh, Y.-T., Rosti, G., Nakamae, H., Gallagher, N. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70201-7 · Cited by 513
Self-citationGambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Self-citationActivity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C., & Boschelli, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8853 · Cited by 399
Self-citation
Metadata
- Authors
- Hochhaus, A., Druker, B., Sawyers, C., Guilhot, F., Schiffer, C. A., Cortes, J., Niederwieser, D. W., Gambacorti-Passerini, C., Stone, R. M., Goldman, J., Fischer, T., O'Brien, S. G., Reiffers, J. J., Mone, M., Krahnke, T., Talpaz, M., & Kantarjian, H. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-02-01
- Volume
- 111
- Issue
- 3
- Pages
- 1039-1043
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1964358866
- Cited by
- 211
- References
- 0
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. https://app.cochat.ai/papers/10.1182/blood-2007-07-103523
- The paper
- Hochhaus, A., Druker, B., Sawyers, C., Guilhot, F., Schiffer, C. A., Cortes, J., Niederwieser, D. W., Gambacorti-Passerini, C., Stone, R. M., Goldman, J., Fischer, T., O'Brien, S. G., Reiffers, J. J., Mone, M., Krahnke, T., Talpaz, M., & Kantarjian, H. M. (2008). Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. https://doi.org/10.1182/blood-2007-07-103523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.